Roche gets CE-mark for v-TAC blood diagnostic product
Roche Holding AG
€0.00
07:46 20/03/24
Roche announced the CE-mark availability of ‘Roche v-TAC’ - a new digital diagnostic solution - on Friday.
The Swiss pharmaceuticals giant said v-TAC allows clinicians to obtain results for arterial blood gas values from patients with respiratory or metabolic abnormalities via a simpler, less invasive venous puncture, through the use of a digital algorithm.
It said blood gas analysis was typically used in hospital point of care settings, where quick and accurate results are needed, including in emergency rooms, intensive care units and operating rooms.
The analysis provides clinicians with information about a patient’s pulmonary function and acid‐base status, both of which are essential to make a diagnosis, provide treatment and monitor progress.
A traditional blood gas test requires the collection of an arterial blood sample, which can be a painful experience for the patient, since most arteries lie deeper in the tissue than veins and have a thicker wall to be punctured, with the procedure usually carried out by medical doctors or specially-trained staff.
Through the Roche v-TAC digital solution, staff without specific training to draw arterial blood samples are now able to withdraw a venous blood sample instead, and digitally convert those values into arterial blood gas values, which can help free up specialist healthcare staff to other tasks.
Roche said v-TAC is fully integrated for use with its ‘cobas b 123 POC’ and ‘cobas b 221’ systems, using the ‘Roche cobas infinity POC’ solution.
“In an emergency situation such as the COVID-19 pandemic, Roche v-TAC could also help healthcare professionals to assess disease severity faster in patients and closely monitor potential deterioration in patients with respiratory compromise,” said Roche Diagnostics chief executive officer Thomas Schinecker.
“Digital tools based on clinical algorithms like Roche v-TAC can help improve and simplify delivery of care in emergency situations faster and where it is most needed.”
Roche acquired the v-TAC technology at the end of March, as part of the acquisition of Danish firm Obi Medical, which focuses on developing disruptive blood gas testing technology.